Abstract: A method for detecting MERS-CoV at high sensitivity and specificity using IgY antibodies that bind to MERS-CoV N protein, its fragments and domains. Isolated or purified IgY monospecific antibodies to MERS-CoV N protein.
Type:
Grant
Filed:
August 19, 2021
Date of Patent:
April 19, 2022
Assignee:
King Abdulaziz University
Inventors:
Ayman Talaat Abbas Abdelhadi, Esam Ibraheem Ahmed Azhar, Sherif Aly Abdelkhalek Elkafrawy, Sayed Sartaj Sohrab
Abstract: This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.
Abstract: A heat-resistant recombinant Newcastle Disease Virus vaccine strain rLS-tFib2-C capable of expressing truncated Fiber 2 protein of fowl adenovirus serotype 4 has been preserved at the China Center for Type Culture Collection, Wuhan University, Wuhan, China with the preservation number of CCTCC No. V202042.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
March 29, 2022
Assignee:
INSTITUTE OF ANIMAL HUSBANDRY AND VETERINARY SCIENCES, HUBEI ACADEMY OF AGRICULTURAL SCIENCES
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
Type:
Grant
Filed:
August 23, 2018
Date of Patent:
March 15, 2022
Assignee:
Bavarian Nordic A/S
Inventors:
Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan
Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
February 15, 2022
Assignee:
Seqirus UK Limited
Inventors:
Mario Contorni, Derek O'Hagan, Nicola Groth
Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
Abstract: The present invention relates to methods for the production of biopharmaceuticals implementing a baculovirus-based system. These methods advantageously allow the production of biopharmaceuticals with a reduced number of or without contaminating baculoviral virions.
Type:
Grant
Filed:
August 27, 2019
Date of Patent:
February 1, 2022
Assignee:
GENETHON
Inventors:
Otto-Wilhelm Merten, Martin Marek, Monique Van Oers
Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
January 25, 2022
Assignees:
The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
Inventors:
Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
Abstract: A vaccine against Mycobacterium tuberculosis (M. tuberculosis) formulated for intranasal administration, comprises a first vaccine component comprising one or more M. tuberculosis, Mycobacterium vaccae (M. vaccae) or Mycobacteroium bovis (M. bovis) antigens, and a second vaccine component comprising a Stimulator of Interferon Genes (STING) activator.
Type:
Grant
Filed:
July 7, 2020
Date of Patent:
January 18, 2022
Assignee:
The Regents of the University of California
Inventors:
Sarah Stanley, Erik Van Dis, Kimberly Sogi, Daniel A. Portnoy, Chris Rae
Abstract: The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion exchange chromatography and tangential flow filtration.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
January 18, 2022
Assignee:
SANOFI PASTEUR BIOLOGICS, LLC
Inventors:
Sophia Mundle, Stephen Anderson, Simon Delagrave
Abstract: Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
January 4, 2022
Inventors:
Boris Farber, Sof'ya Farber, Artur Viktorovich Martynov
Abstract: Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
December 28, 2021
Assignees:
Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
December 28, 2021
Assignee:
Valneva SE
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
December 28, 2021
Assignee:
EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
Inventors:
Michael Schindler, Marius Codrea, Sven Nahnsen, Herwig Koppensteiner, Gundram Jung, Martin Hofmann